Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) Meeting Abstract


Authors: Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; Burke, M. M.; Ralabate, A. L.; Rivera, A. L.; Kronenberg, S. A.; Agunwamba, B.; Feely, W.; Hong, Q.; Krishnan, S.; Gupta, A. K.; Wolchok, J. D.
Abstract Title: Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
Meeting Title: 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 32
Issue: 15 Suppl.
Meeting Dates: 2014 May 30-Jun 3
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2014-05-20
Language: English
ACCESSION: WOS:000358613201965
PROVIDER: wos
Notes: Meeting Abstract: LBA9003^ -- Source: Wos
MSK Authors
  1. Jedd D Wolchok
    607 Wolchok
  2. Neil Howard Segal
    94 Segal
  3. Michael Andrew Postow
    175 Postow
  4. Naiyer A Rizvi
    150 Rizvi
  5. Ruth-Ann Roman
    26 Roman
  6. Alexander Meyer Lesokhin
    106 Lesokhin
  7. Margaret M Burke
    2 Burke